MiNK Therapeutics surges over 700% after testicular cancer remission data fuels iNKT therapy optimism

MiNK Therapeutics, Inc. (NASDAQ: INKT) witnessed a dramatic surge of 730% during regular trading hours on July 11, 2025, closing at $64.17 from a previous close of $7.73. The spike followed the publication of a clinical case in Oncogene that reported complete and sustained remission in a patient with metastatic, treatment-refractory testicular cancer after receiving the American biotech company’s allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797. The case highlighted the potential of MiNK’s off-the-shelf cell therapy platform to succeed where chemotherapy, stem cell transplant, and immune checkpoint inhibitors had failed.

The surge in MiNK Therapeutics stock made it one of the biggest daily gainers across all U.S. exchanges. However, after-hours trading showed some profit-taking, with the stock declining 19.74% to $51.50.

What did the latest MiNK Therapeutics clinical update reveal about agenT-797’s anti-tumor activity?

The publication, titled “Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor,” detailed the case of a patient enrolled in MiNK’s clinical trial (NCT05108623) who achieved full remission after a single infusion of agenT-797 in combination with nivolumab. The patient had previously progressed on platinum-based chemotherapy, autologous stem cell transplant, and three classes of immune checkpoint inhibitors: anti–PD-1, anti–CTLA-4, and anti–TIGIT.

Two years after the treatment, there remained no evidence of disease, and donor iNKT cells were still detectable in the patient’s system for up to six months. Importantly, the therapy was well-tolerated, with no incidence of cytokine release syndrome (CRS) or graft-versus-host disease (GVHD)—two serious risks often associated with allogeneic immune therapies.

This case builds on earlier evidence presented at the 2025 AACR Immuno-Oncology meeting, where MiNK Therapeutics showcased positive Phase 2 data in second-line gastric cancer patients. Those results demonstrated immune activation, improved tumor infiltration, and prolonged survival in a subset of patients who had failed prior immunotherapy.

Why are investors treating this case report as a major validation moment for MiNK Therapeutics?

While single-patient case studies are rarely sufficient to confirm therapeutic viability at scale, the context of this remission—in a heavily pretreated patient population with few alternatives—offers compelling preliminary evidence for agenT-797’s mechanism. The American biotech company’s use of iNKT cells, which bridge both innate and adaptive immunity, sets it apart from conventional T-cell and CAR-T approaches.

Institutional investors likely viewed the publication as a clinical de-risking event, with the remission outcome demonstrating real-world therapeutic potential. The stock’s 47.5 million share volume—massively above its 7,500 average daily volume—indicates extraordinary retail and algorithmic interest. Analysts also noted that the successful use of an allogeneic platform without CRS or GVHD could streamline future scalability and regulatory approval pathways.

How does agenT-797 differ from other cell therapies in development for solid tumors?

AgenT-797 leverages invariant natural killer T cells that act as “master regulators,” combining the direct cytotoxicity of NK cells with the antigen specificity and memory function of T cells. Unlike autologous CAR-T therapies that require weeks of personalized manufacturing, MiNK’s product is cryopreserved and off-the-shelf, allowing for immediate deployment.

In ongoing trials, agenT-797 has shown promise not just in cancer but also in graft-versus-host disease and pulmonary inflammation, further expanding its therapeutic footprint. According to MiNK Therapeutics, the therapy’s pathogen-agnostic response and tumor infiltration capabilities suggest a differentiated profile suited to complex immunosuppressive microenvironments like those found in metastatic cancers.

With its manufacturing facility in Lexington, Massachusetts, MiNK Therapeutics claims to have a scalable process in place to meet potential future demand across indications.

What are the next clinical and regulatory milestones that investors should track for MiNK Therapeutics?

The ongoing Phase 2 gastric cancer trial (NCT06251973) remains a crucial near-term readout for the oncology-focused drugmaker. The trial is actively enrolling, and management has guided for additional updates in the coming months. Investors will be watching closely for broader cohort efficacy signals, particularly in patients who previously failed on checkpoint inhibitors.

Additionally, MiNK Therapeutics is developing a suite of precision-targeted immune therapies and TCR-based products, which could enable expansion into neoantigen-directed oncology and autoimmune disorders. While no regulatory filings have yet been announced, the company’s recent data may justify breakthrough designation or orphan drug applications in select indications.

Market watchers are also anticipating new partnership announcements or capital raises, especially following the sharp rise in market cap from under $60 million to over $250 million in a single session.

How are institutional and retail investors interpreting the stock’s 730% intraday surge and sharp after-hours decline?

Despite the 730.14% intraday rally, the after-hours decline of nearly 20% underscores the volatility often associated with thinly traded biotech stocks. The day’s range stretched from $20.20 to $76.00, reflecting both exuberance and caution among traders. Institutional sentiment appears cautiously optimistic, with analysts citing the need for larger cohort data before assigning long-term value.

Retail investor forums lit up with speculation and momentum plays, drawing comparisons to past immuno-oncology breakout stocks. However, the relatively low float and thin liquidity of MiNK Therapeutics amplified price swings. Experts caution that while the testicular cancer result is significant, broader validation through multi-patient datasets remains essential.

What is the broader significance of MiNK’s iNKT platform in the context of cell therapy’s evolution?

MiNK Therapeutics represents a next-generation approach to cell therapy that may overcome several limitations of CAR-T and TIL (tumor-infiltrating lymphocyte) modalities. The durability of response in checkpoint-refractory solid tumors, the lack of toxic cytokine storms, and the ready-to-use nature of the product could reshape expectations in oncology pipelines.

Analysts expect that if subsequent data supports these early signals, larger biotech and pharma players may pursue partnerships or acquisitions to gain access to the iNKT platform. Moreover, if agenT-797 succeeds in trials for pulmonary inflammation or GvHD, the platform’s versatility could justify expansion beyond oncology.

For now, MiNK Therapeutics has re-entered the biotech spotlight, transforming overnight from a microcap obscurity into a high-momentum immunotherapy contender.